Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.42B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 1.49M
Average 2.86M
VRDN Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Viridian Therapeutics, Inc.NASDAQ: VRDN
Other Income / Expenses · Q2 FY2026 · quarter ended Jun 2026
Other income / expenses turns negative
Q2 FY2026 other income / expenses was -$851K, compared with $6.03M a year earlier. Trailing-twelve-month other income / expenses was $18.23M. Over 3 fiscal years it compounded at +67.4% a year.
Context
- Other income / expenses amounted to 29.3% of revenue in FY2025, down 9601.8 pp from a year earlier.
- Other income / expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly other income / expenses holds near -$851K or moves back toward the trailing-twelve-month quarterly average of $4.56M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 20.79M USD
- Year-over-year change
- -28.5%
- 4-year CAGR
- +185.0%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.79M | -28.5% |
| FY2024 | 2024-12-31 | 29.09M | +74.0% |
| FY2023 | 2023-12-31 | 16.72M | +277.3% |
| FY2022 | 2022-12-31 | 4.43M | +1306.3% |
| FY2021 | 2021-12-31 | 315K | — |
Other Income / Expenses vs competitors
How VRDN compares with its peers on the latest reported figures
- VRDN's LTM Jun 2026 other income / expenses of $18.23M is the highest of the 4 companies compared; the peer median is $8.94M.
- Its year-over-year change of -33.8% is the 3rd highest of 4, against a peer median of -28.8%.
- Other income / expenses amounts to 25.6% of revenue for VRDN, versus a peer median of 137.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.23M | -33.8% | +67.4% | 25.6% | |
| LTM Mar 2026 | $10.45M | -28.8% | — | 137.3% | |
| LTM Mar 2026 | $8.94M | -21.4% | -18.8% | 17.2% | |
| LTM Mar 2026 | -$1.94M | -102.0% | — | 581.4% | |
| Peer median (excluding VRDN) | $8.94M | -28.8% | -18.8% | 137.3% | |
Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.96M | 1.77M | 314K | 302K | 70.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.96M | 1.77M | 314K | 302K | 70.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 56.89M | 100.89M | 159.77M | 238.25M | 338.93M |
| Selling, General & Admin | 25.81M | 35.18M | 95M | 61.08M | 95.32M |
| Operating Expenses | 82.69M | 136.08M | 254.76M | 299.34M | 434.24M |
| Depreciation & Amortization | 120K | 255K | 522K | 540K | 460K |
| EBITDA | (79.29M) | (129.13M) | (235.37M) | (266.36M) | (337.19M) |
| EBITDA Margin | -2676.0% | -7287.4% | -74957.0% | -88199.7% | -475.9% |
| Operating Income | (79.73M) | (134.3M) | (254.45M) | (299.04M) | (363.4M) |
| Operating Margin | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Interest Income | 318K | 4.92M | 18.56M | 32.13M | 27.4M |
| Interest Expense | 3K | 486K | 1.85M | 3.05M | 4.95M |
| Other Income / Expenses | 315K | 4.43M | 16.72M | 29.09M | 20.79M |
| Income Before Tax | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Pre-Tax Margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Net Margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| EPS (Basic) | (6.66) | (3.91) | (5.31) | (3.98) | (3.32) |
| EPS (Diluted) | (6.66) | (3.91) | (5.31) | (3.98) | (3.32) |
| Weighted Avg Shares | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M |
| Weighted Avg Shares (Diluted) | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M |
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Intrinsic Alpha fair value
Locked
Current Price
$30.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.